US Physical Therapy
The 10-second takeaway
For the quarter ended June 30 (Q2), US Physical Therapy met expectations on revenues and missed estimates on earnings per share.
Compared to the prior-year quarter, revenue increased and GAAP earnings per share was unchanged.
Margins dropped across the board.
Revenue details
US Physical Therapy reported revenue of $64.0 million. The six analysts polled by S&P Capital IQ hoped for revenue of $63.9 million on the same basis. GAAP reported sales were 6.8% higher than the prior-year quarter's $59.9 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS details
EPS came in at $0.41. The six earnings estimates compiled by S&P Capital IQ forecast $0.44 per share. GAAP EPS of $0.41 were the same as the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
Margin details
For the quarter, gross margin was 28.6%, 40 basis points worse than the prior-year quarter. Operating margin was 16.6%, 160 basis points worse than the prior-year quarter. Net margin was 7.6%, 60 basis points worse than the prior-year quarter.
Looking ahead
Next quarter's average estimate for revenue is $63.2 million. On the bottom line, the average EPS estimate is $0.38.
Next year's average estimate for revenue is $252.9 million. The average EPS estimate is $1.55.
Investor sentiment
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 245 members out of 249 rating the stock outperform, and four members rating it underperform. Among 72 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 70 give US Physical Therapy a green thumbs-up, and two give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on US Physical Therapy is buy, with an average price target of $29.50.
- Add US Physical Therapy to My Watchlist.
